APA (7th ed.) Citation

GWJ, S., J, X., JP, S., J, R., RL, M., MB, L., . . . D, S. (2025). Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: A large real-world data analysis. Breast cancer research : BCR, 27(1), 144. https://doi.org/10.1186/s13058-025-02094-7

Chicago Style (17th ed.) Citation

GWJ, Sledge, Xiu J, Solzak JP, Ribeiro J, Mahtani RL, Lustberg MB, Oberley MJ, Radovich M, and Spetzler D. "Comparison of Trastuzumab Deruxtecan and Sacituzumab Govitecan in HER2-negative Metastatic Breast Cancer: A Large Real-world Data Analysis." Breast Cancer Research : BCR 27, no. 1 (2025): 144. https://doi.org/10.1186/s13058-025-02094-7.

MLA (9th ed.) Citation

GWJ, Sledge, et al. "Comparison of Trastuzumab Deruxtecan and Sacituzumab Govitecan in HER2-negative Metastatic Breast Cancer: A Large Real-world Data Analysis." Breast Cancer Research : BCR, vol. 27, no. 1, 2025, p. 144, https://doi.org/10.1186/s13058-025-02094-7.